|
|
Prepublished online as a Blood First Edition Paper on July 5, 2002; DOI 10.1182/blood-2002-04-1133.
 Previous Article | Table of Contents | Next Article 
Blood, 15 November 2002, Vol. 100, No. 10, pp. 3495-3503
HEMATOPOIESIS
Prominent role of TGF- 1 in
thrombopoietin-induced myelofibrosis in mice
Hédia Chagraoui,
Emiko Komura,
Micheline Tulliez,
Stéphane Giraudier,
William Vainchenker, and
Françoise Wendling
From INSERM U362, Institut Gustave Roussy, Villejuif,
France; and Hôpital Cochin, Laboratoire
d'Anatomopathologie, Paris, France.
Several studies suggest an implication of transforming growth
factor- 1 (TGF-1) in the promotion of myelofibrosis associated with hematopoietic malignancies, but the involvement of this cytokine is not fully investigated. To test directly the impact of TGF-1 in
the pathogenesis of myelofibrosis, bone marrow stem cells from homozygous TGF-1 null (TGF-1 /) and wild-type (WT)
littermates were infected with a retrovirus encoding the murine
thrombopoietin (TPO) protein and engrafted into lethally irradiated
wild-type hosts for long-term reconstitution. Over the 4 months of
follow-up, TPO levels in plasma were markedly elevated in both groups
of mice, and animals typically developed a myeloproliferative syndrome
characterized by thrombocytosis, leukocytosis, splenomegaly, increased
numbers of progenitors in blood, and extramedullary hematopoiesis.
Severe fibrosis was observed in spleen and marrow from all the mice
engrafted with WT cells. In contrast, none of the mice repopulated with
TGF-1/ cells (chimerism > 70%) showed deposition
of reticulin fibers at any time during the follow-up. In accordance
with the development of fibrosis, latent TGF-1 levels in plasma and
extracellular fluid of the spleen from mice engrafted with WT cells
were increased 6-fold and 4-fold, respectively, over levels found in
normal hosts, whereas no increase over baseline levels could be
demonstrated in animals undergoing transplantation with
TGF-1/ cells. These data provide evidence that
TGF-1 produced by hematopoietic cells is pivotal for the
pathogenesis of myelofibrosis that develops in mice with TPO overexpression.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
O. Bock, J. Hoftmann, K. Theophile, K. Hussein, B. Wiese, J. Schlue, and H. Kreipe
Bone Morphogenetic Proteins Are Overexpressed in the Bone Marrow of Primary Myelofibrosis and Are Apparently Induced by Fibrogenic Cytokines
Am. J. Pathol.,
April 1, 2008;
172(4):
951 - 960.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. O. Ciurea, D. Merchant, N. Mahmud, T. Ishii, Y. Zhao, W. Hu, E. Bruno, G. Barosi, M. Xu, and R. Hoffman
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis
Blood,
August 1, 2007;
110(3):
986 - 993.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Cairo
Myelofibrosis with myeloid metaplasia: targeted therapy
Blood,
July 1, 2007;
110(1):
2 - 3.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Wagner-Ballon, D. F. Pisani, T. Gastinne, M. Tulliez, R. Chaligne, C. Lacout, F. Aurade, J.-L. Villeval, P. Gonin, W. Vainchenker, et al.
Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice
Blood,
July 1, 2007;
110(1):
345 - 353.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Chang, F. Aurade, F. Larbret, Y. Zhang, J.-P. Le Couedic, L. Momeux, J. Larghero, J. Bertoglio, F. Louache, E. Cramer, et al.
Proplatelet formation is regulated by the Rho/ROCK pathway
Blood,
May 15, 2007;
109(10):
4229 - 4236.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi
Primary myelofibrosis and its paraneoplastic stromal effects
Haematologica,
May 1, 2007;
92(5):
577 - 579.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Zetterberg, A. M. Vannucchi, A. R. Migliaccio, W. Vainchenker, M. Tulliez, R. Dickie, H. Hasselbalch, R. Rogers, and J. Palmblad
Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows
Haematologica,
May 1, 2007;
92(5):
597 - 604.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Nakayama, N. Mutsuga, and G. Tosato
Effect of Fibroblast Growth Factor 2 on Stromal Cell-Derived Factor 1 Production by Bone Marrow Stromal Cells and Hematopoiesis
J Natl Cancer Inst,
February 7, 2007;
99(3):
223 - 235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Hoffman and D. Rondelli
Biology and Treatment of Primary Myelofibrosis
Hematology,
January 1, 2007;
2007(1):
346 - 354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Kennedy, F. Barabe, B. J. Patterson, J. Bayani, J. A. Squire, D. L. Barber, and J. E. Dick
Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo
PNAS,
November 7, 2006;
103(45):
16930 - 16935.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lacout, D. F. Pisani, M. Tulliez, F. M. Gachelin, W. Vainchenker, and J.-L. Villeval
JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis
Blood,
September 1, 2006;
108(5):
1652 - 1660.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, G. Barosi, R. A. Mesa, F. Cervantes, H. J. Deeg, J. T. Reilly, S. Verstovsek, B. Dupriez, R. T. Silver, O. Odenike, et al.
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
Blood,
September 1, 2006;
108(5):
1497 - 1503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, J. Cortes, S. Verstovsek, R. A. Mesa, D. Thomas, T. L. Lasho, W. J. Hogan, M. R. Litzow, J. B. Allred, D. Jones, et al.
Lenalidomide therapy in myelofibrosis with myeloid metaplasia
Blood,
August 15, 2006;
108(4):
1158 - 1164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Dong and G. C. Blobe
Role of transforming growth factor-beta in hematologic malignancies
Blood,
June 15, 2006;
107(12):
4589 - 4596.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Wagner-Ballon, H. Chagraoui, E. Prina, M. Tulliez, G. Milon, H. Raslova, J.-L. Villeval, W. Vainchenker, and S. Giraudier
Monocyte/Macrophage Dysfunctions Do Not Impair the Promotion of Myelofibrosis by High Levels of Thrombopoietin.
J. Immunol.,
June 1, 2006;
176(11):
6425 - 6433.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. I. Schafer
Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia
Blood,
June 1, 2006;
107(11):
4214 - 4222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Staerk, C. Lacout, T. Sato, S. O. Smith, W. Vainchenker, and S. N. Constantinescu
An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor
Blood,
March 1, 2006;
107(5):
1864 - 1871.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Martelli, B. Ghinassi, B. Panetta, E. Alfani, V. Gatta, A. Pancrazzi, C. Bogani, A. M. Vannucchi, F. Paoletti, G. Migliaccio, et al.
Variegation of the phenotype induced by the Gata1low mutation in mice of different genetic backgrounds
Blood,
December 15, 2005;
106(13):
4102 - 4113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi
Pathogenesis of Myelofibrosis With Myeloid Metaplasia
J. Clin. Oncol.,
November 20, 2005;
23(33):
8520 - 8530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Vannucchi, A. Pancrazzi, P. Guglielmelli, S. Di Lollo, C. Bogani, G. Baroni, L. Bianchi, A. R. Migliaccio, A. Bosi, and F. Paoletti
Abnormalities of GATA-1 in Megakaryocytes from Patients with Idiopathic Myelofibrosis
Am. J. Pathol.,
September 1, 2005;
167(3):
849 - 858.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Vannucchi, L. Bianchi, F. Paoletti, A. Pancrazzi, E. Torre, M. Nishikawa, M. Zingariello, A. Di Baldassarre, R. A. Rana, R. Lorenzini, et al.
A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-{beta}1 in the development of myelofibrosis
Blood,
May 1, 2005;
105(9):
3493 - 3501.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Komura, C. Tonetti, V. Penard-Lacronique, H. Chagraoui, C. Lacout, J. P. LeCouedic, P. Rameau, N. Debili, W. Vainchenker, and S. Giraudier
Role for the Nuclear Factor {kappa}B Pathway in Transforming Growth Factor-{beta}1 Production in Idiopathic Myelofibrosis: Possible Relationship with FK506 Binding Protein 51 Overexpression
Cancer Res.,
April 15, 2005;
65(8):
3281 - 3289.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Centurione, A. Di Baldassarre, M. Zingariello, D. Bosco, V. Gatta, R. A. Rana, V. Langella, A. Di Virgilio, A. M. Vannucchi, and A. R. Migliaccio
Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1low mice
Blood,
December 1, 2004;
104(12):
3573 - 3580.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sabri, M. Jandrot-Perrus, J. Bertoglio, R. W. Farndale, V. M.-D. Mas, N. Debili, and W. Vainchenker
Differential regulation of actin stress fiber assembly and proplatelet formation by {alpha}2{beta}1 integrin and GPVI in human megakaryocytes
Blood,
November 15, 2004;
104(10):
3117 - 3125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. O'Brien, A. Tefferi, and P. Valent
Chronic Myelogenous Leukemia and Myeloproliferative Disease
Hematology,
January 1, 2004;
2004(1):
146 - 162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. Deeg, T. A. Gooley, M. E. D. Flowers, G. E. Sale, J. T. Slattery, C. Anasetti, T. R. Chauncey, K. Doney, G. E. Georges, H.-P. Kiem, et al.
Allogeneic hematopoietic stem cell transplantation for myelofibrosis
Blood,
December 1, 2003;
102(12):
3912 - 3918.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-C. Martyre, V. Steunou, M.-C. LeBousse-Kerdiles, J. Wietzerbin, A. M. Vannucchi, and A. R. Migliaccio
Lack of alteration in GATA-1 expression in CD34+ hematopoietic progenitors from patients with idiopathic myelofibrosis
Blood,
June 15, 2003;
101(12):
5087 - 5089.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi
The Forgotten Myeloproliferative Disorder: Myeloid Metaplasia
Oncologist,
June 1, 2003;
8(3):
225 - 231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Chagraoui, M. Tulliez, T. Smayra, E. Komura, S. Giraudier, T. Yun, N. Lassau, W. Vainchenker, and F. Wendling
Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO
Blood,
April 15, 2003;
101(8):
2983 - 2989.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Spivak, G. Barosi, G. Tognoni, T. Barbui, G. Finazzi, R. Marchioli, and M. Marchetti
Chronic Myeloproliferative Disorders
Hematology,
January 1, 2003;
2003(1):
200 - 224.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
